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Introduction   
The occurrence of  donor-origin malignancy in a trans-
plant recipient is rare. [1-2] With melanoma, the disease 
can be very aggressive.  Sometimes the melanoma can be 
“cured” following allograft removal and cessation of  im-
munosuppression.  [3-8]  There are few reports of  this in 
the radiology literature and, to our knowledge, none that 
provide serial CT imaging over the course of  disease pro-
gression and regression. [5] We report such a case and pro-
vide pathologic correlation from liver mass biopsies.
Case Report
A 46-year-old white male presented to our institution 
with membranous glomerulonephropathy, diagnosed sev-
eral years earlier by renal biopsy.  He received immunosup-
pressive therapy with cytoxan and prednisone; however, 
over a two-year period his renal insufficiency progressed to 
end-stage renal disease.  Refusing any hemodialysis treat-
ment, he received a living related donor renal transplant 
from his brother, who was a zero match.  Surgery was with-
out complication.  Soon after surgery, the donor developed 
neurological deficits.  His work-up was positive for meta-
static melanoma to brain with an unknown primary site.  
Allograft removal was advised, but our patient did not 
wish to undergo hemodialysis, and therefore opted to keep 
the donor kidney and undergo surveillance with serial ab-
domen /pelvic CT scans.  Patient did well clinically on 
immunosuppression therapy.  Abdomen/pelvic CT scan at 
three months post transplant was negative for malignancy, 
showing only a 1.5-cm benign-appearing cyst within the 
allograft.  CT scans six months post transplant showed no 
significant change.  The next CT exam at one year post 
transplant, revealed several masses within the allograft 
(Figure 1), which appeared solid by ultrasound examina-
tion.  Additionally, several prominent lymph nodes were 
noted at the hilum and adjacent to the upper pole of  the 
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Figure 1.  CT one year after transplant  showing several 
new masses within the renal allograft. 
allograft.  Several small, low-density lesions were also ap-
preciated in the spleen.  An ultrasound-guided biopsy (18-
gauge needle) was obtained from one of  the allograft le-
sions and was positive for malignant melanoma. 
The patient underwent exploratory laparotomy with al-
lograft nephrectomy, splenectomy, right hemicolectomy, 
and liver biopsy revealing diffuse melanoma involving the 
allograft, liver, spleen, mesocolon and para-aortic lymph 
nodes.  He was started on hemodialysis.  CT scans were 
performed at three month intervals for two years, then at 
six months intervals thereafter.  The first hepatic metastasis 
visible on CT (Figure 2a), in the lateral left lobe, was seen at 
the first three month follow-up, after the allograft nephrec-
tomy (approximately 15 months after the transplant .)  
Other metastases became visible later (Figure 3a).  As these 
metastases were followed with CT, they eventually became 
calcified and smaller, consistent with remission/rejection 
(Figures 2 and 3).  A biopsy of  one of  the hepatic metasta-
ses was performed approximately 3.5 years after the allo-
graft nephrectomy and cessation of  immunosuppressive 
therapy, showing abundant melanin pigment, but no ma-
lignancy. (Figure 4) Trial immunosuppressive therapy was 
begun and a liver biopsy six months later also was negative 
for malignancy.  After a successful trial of  the immunosup-
pressive therapy for one year, there was no evidence of  re-
currence and he was cleared for transplant.  However, no 
suitable donor was found.  Due to chronic illness and car-
diovascular compromise, he was removed from the trans-
plant list about two years later and continued dialysis until 
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Figure 2A.  CT images at the level of a left lobe liver metas-
tasis (arrow) and small incidental cyst (arrowhead). At 15 
months after transplant
2B 2C
Figure 2.  CT images at the level of a left lobe liver metastasis (arrow) and small incidental cyst  (arrowhead). B. At 30 months 
after transplant with decreasing size and central calcification within the metastasis.  C. At 42 months after transplant with com-
plete calcification of the metastasis.  
Auto-Rejection of Renal Donor-Origin Metastatic Melanoma
RCR Radiology Case Reports | radiology.casereports.net 151 2006:1(4):149-153
3A 3B
3C
Figure 3.  CT images showing a periportal metastasis (ar-
row) and a peripheral metastasis (arrowhead).   A. At 18 
months after transplant.  B. At 30 months after transplant 
showing increased size of the periportal metastasis  with rim 
calcification.   Peripheral metastasis now present with calci-
fication.  C. At  42 months after transplant showing de-
creased size and increased rim calcification of the periportal 
metastasis.  Peripheral metastasis  now completely calci-
fied.
his death from heart disease three years later.  He survived 
11 years following the initial surgery for metastatic mela-
noma.
Discussion
Transplantation of  organs with known and undetected 
donor neoplasms have been well documented in the litera-
ture [1-3,9-10]  We found only one report in the radiology 
literature, demonstrating donor-origin metastatic disease to 
a transplant kidney. [5]  Excluding primary brain neo-
plasm, this occurs rarely; 1.3% of  transplants in one study 
[1] and only 0.5% in another [2].   Clearly, the transplant 
recipient on immunosuppression therapy provides a “fertile 
field” for growth and dissemination of  foreign tumor cells.  
When an organ is transplanted from a donor with extra-
cerebral malignancy, the chance of  tumor cell transmission 
is high, calculated at 44% by Penn [3].  This may be even 
higher with melanoma, with one report showing transmis-
sion of  tumor cells to 17 of  20 kidney recipients from 11 
donors with melanoma.  [4]  
It is therefore recommended that immediate removal of  
the allograft be performed with discontinuation of  immu-
nosuppression therapy in the hope that any remaining 
transplanted tumor cells would be rejected by the recipients 
immune system [3].  However, if  allograft removal is ini-
tially refused, as in our case, or if  allograft removal is not 
feasible (e.g. liver transplant), the patient needs to be evalu-
ated at regular intervals with CT or MRI.  The optimal 
frequency of  radiologic surveillance exams remains unclear.  
However, it was evident, in our case that significant pro-
gression of  disease occurred during the 6-month interval 
from 6 months to one year post transplant.  Perhaps, radio-
logic screening at 3-month intervals should continue for at 
least the first year post transplant, if  not longer. 
There are reports of  complete remission following allo-
graft removal and cessation of  immunosuppression therapy 
as with our patient, but some patients have required immu-
notherapy or chemotherapy to eradicate the transmitted 
melanoma.  [4-8]  Still, most of  the reported patients died 
from the melanoma.  There have been no reports demon-
strating the radiographic regression of  liver metastases on 
CT from donor transmitted melanoma, to our knowledge.  
However, there has been a report of  resolution of  meta-
static nodules on chest x-ray. [7]  They did not report any 
residual calcification.  In our case, with regression of  the 
liver metastases, the size decreased and dense calcification 
developed, similar to old granulomatous disease.  Our biop-
sies proved no active malignancy, even though melanin was 
still present.  Of  interest, a year long trial of  immunosup-
pression showed no recurrence radiographically or on re-
peat liver biopsy, indicating repeat transplantation could be 
performed successfully.  A second successful transplant in 
such a patient has been reported.  [7]
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Figure 4. A.  Microscopic image showing residual melanin in the liver (arrowhead) surrounded by scarring, but no residual ma-
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